Company intelligence / Profile preview

Inbiose

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

The company has reached commercial scale production and achieved key regulatory approvals but continues to develop additional specialty glycan products.

Therapeutic areas: Metabolic DisordersGastroenterologyOther
Modalities: Specialty glycans (complex carbohydrates)Human Milk Oligosaccharides (HMOs)
Industry: Non-Drug Biotech

Drug pipeline

2 assets

2-fucosyllactose

Commercial

Indications: Infant nutrition

1 more asset in the full pipeline.

Request access →

Partnerships

Not explicitly listed; as a B2B supplier they likely partner with infant formula manufacturers and food/nutrition companies.

Beyond the preview

Go deeper on Inbiose.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inbiose.

Explore the full profile